Discovery of LG-NE-29: An Orally Bioavailable GSPT1 Molecular Glue Degrader Effective in Glioblastoma Xenograft Models
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c00544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Taiting Shi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China. Hauptthemen laut MEDLINE: Glioblastoma, Antineoplastic Agents, Drug Discovery, Brain Neoplasms. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Lingang, Science and Technology Commission of Shanghai Municipality, Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
The clinical management of glioblastoma (GBM) is severely hindered by rapid resistance to temozolomide (TMZ). Through viability-based phenotypic screening, we identified the translation termination factor GSPT1 (G1 to S phase transition 1) as a critical vulnerability in GBM cells. Structure−activity relationship optimization of an isoindolinone scaffold, specifically focused on improving metabolic stability, led to the discovery of LG-NE-29, a potent molecular glue degrader. This compound efficiently promotes CRBN-dependent ubiquitination and subsequent proteasomal degradation of GSPT1. LG-NE-29 overcomes the metabolic liabilities of early-generation scaffolds, exhibiting an optimized pharmacokinetic profile highlighted by excellent oral bioavailability (F = 76%). Mechanistically, GSPT1 depletion triggers a profound integrated stress response and intrinsic apoptosis. In U87MG xenograft models, oral administration of LG-NE-29 induced significant tumor regression. Collectively, these findings validate GSPT1 as an actionable therapeutic target in GBM and establish LG-NE-29 as a robust pharmacological tool for further targeted protein degradation research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China.
- Lingang Laboratory, Shanghai200031, China.
- School of Physical Science and Technology, ShanghaiTech University, Shanghai201210, China.
- School of Life Science and Technology, ShanghaiTech University, Shanghai201210, China.
- Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai20…
ORCID-Profile: Xueying Gong, Zhanchao Meng, Wenchao Lu
Förderung
- Lingang
- Science and Technology Commission of Shanghai Municipality
- Zhejiang Provincial Natural Science Foundation of China
- Discipline Cluster of Oncology, Wenzhou Medical University
- Lingang Laboratory
Zitieren
APA
Shi, T., Pei, Y., Peng, B., Wu, Z., Feng, Y., Zhao, Y., Luo, Y., Chen, Q., Chen, S., Xu, J., Shao, Z., Liu, Y., Gong, X., Yang, S., Zou, X., Zhou, L., Zhao, Y., Jiang, H., Xu, C., …, & Su, Z. (2026). Discovery of LG-NE-29: An Orally Bioavailable GSPT1 Molecular Glue Degrader Effective in Glioblastoma Xenograft Models. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c00544
Vancouver
Shi T, Pei Y, Peng B, Wu Z, Feng Y, Zhao Y, et al. Discovery of LG-NE-29: An Orally Bioavailable GSPT1 Molecular Glue Degrader Effective in Glioblastoma Xenograft Models. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c00544
BibTeX
@article{Shi2026,
author = {Shi, Taiting and Pei, Yuanyuan and Peng, Bo and Wu, Zerui and Feng, Yixuan and Zhao, Yue and Luo, Yangyu and Chen, Qi and Chen, Songyan and Xu, Jing and Shao, Zhuang and Liu, Yuhang and Gong, Xueying and Yang, Shuke and Zou, Xiaoxiao and Zhou, Lixin and Zhao, Yue and Jiang, Hewei and Xu, Chunlong and Meng, Zhanchao and Lu, Wenchao and Su, Zhipeng},
title = {Discovery of LG-NE-29: An Orally Bioavailable GSPT1 Molecular Glue Degrader Effective in Glioblastoma Xenograft Models},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c00544}
}
EUVIMED